FENIMIDE, a succinimide derivative, is an antipsychotic drug. It is not found in any pharmaceutical preparations sold in the US. It was found that FENIMIDE produced a sedative effect prior to deeper central nervous system depression.

Butoprozine increased the action potential duration like amiodarone, depressed the plateau phase like verapamil and decreased the amplitude and the maximum rate of depolarization. Butoprozine injected intravenously depressed sino-atrial node function, lengthened A-V nodal conduction time and the A-V nodal refractory period, and prolonged the atrial refractory period. Thus butoprozine acted preferentially on parts of the myocardial tissue where the slow inward current seems to be particularly involved. In this respect, butoprozine was more active than amiodarone, but in contrast to this drug, butoprozine did neither prolong the ventricular monophasic action potential duration nor the ventricular refractory period.

Betamethadol or β-methadol is an opioid analgesic under international control according to the UN Single Convention 1961. Betamethadol is an isomer of the racemic mixture of dimepheptanol.

Tinisulpride is a sulfamoylbenzoic acid patented by Fabre, Pierre, S. A. as an antiemetic agent.

Ethonam is an antifungal compound. Its activity was evaluated in the treatment of chronic athlete's foot.

Bisaramil, an antiarrhythmic drug was developed as an inhibitor of calcium transport and as a membrane stabilizer. In addition, the drug showed tonic and frequency-dependent block that is most potent against the heart Na+ channel. However, the phase-II for Arrhythmias in Japan was discontinued.

Aloracetam [CAS 493] is a nootropic agent with potential in the treatment of Alzheimer's disease. Aloracetam was undergoing clinical evaluation with Hoechst for the treatment of Alzheimer's disease, but this research was discontinued later.

Iminophenimide is a piperazinedione derivative patented by American Cyanamid Co. as anticonvulsant.

Almurtide (CGP 11637) is a synthetic muramyl dipeptide (MDP) analogue with potential immunostimulating and antineoplastic activity. As a derivative of the mycobacterial cell wall component MDP, almurtide activates both monocytes and macrophages. This results in the secretion of cytokines and induces the recruitment and activation of other immune cells, which may result in indirect tumoricidal or cytostatic effects. CGP 11637 has been shown to prevent oncogenic viral infections in mice.

Torcetrapib is a CETP inhibitor which was developed by Pfizer for the treatment of diseases associated with elevated level of cholesterol. The drug was tested in phase III (in combination with atorvastatin) of clinical trials in coronary heart disease patients as well as in patients with hyperlipoproteinemia, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, however its development was terminated due to the high risk of death and heart problems.